Live
Last cycle 15h agoMacro: NEUTRAL · 65/100
Net account value$501Live prices
MOSTLYNOevidence before excitement

Skeptical stock research built to show the work, publish the misses, and make a useful no as valuable as a rare yes.

Research and education only — not investment advice.

learnabout MostlyNomethodologyworkshop logMCP
usecheck a stockgaragearenaprosupport
·
about the project

Most stock tools are built to say something. MostlyNo is built to say something worth acting on.

MostlyNo is skeptical stock-research software. It studies public filings, values businesses conservatively, publishes the reasons against a position, and is comfortable ending with no.

check a stock →see the public proof

what MostlyNo is for

Better decisions by reducing false confidence, not by increasing activity.

01Check whether a stock deserves more research.
02See the strongest case against your own thesis.
03Know what price or evidence would change the answer.

the operating principles

Restraint is part of the product.

MostlyNo is designed around incentives that make it harder to manufacture certainty, urgency, or a convenient success story.

01

A useful no is a result.

Most research products are rewarded for producing ideas. MostlyNo is allowed to conclude that nothing is attractive today.

02

The answer is public, not personalized.

Every visitor sees the same verdict. No hidden premium opinion, no portfolio-specific instruction, and no paid influence over the result.

03

Claims must survive time.

Calls are timestamped, disagreements are scored later, and failed ideas stay visible. The record is part of the product.

from filing to verdict

A repeatable pipeline, not a chatbot mood.

The language models debate and explain. The financial data, valuation rules, and risk controls decide what can survive.

1

Read

SEC filings and financial history before headlines or narratives.

2

Value

Sector-aware bear, base, and bull scenarios with conservative assumptions.

3

Challenge

Independent models argue the case and expose where the evidence is weak.

4

Veto

Forensic and downside checks can block a positive conclusion outright.

5

Publish

One plain-language verdict, one timestamp, and a public trail.

The detailed methodology is public. Exact proprietary thresholds, prompts, and execution rules are not.

read the methodology →

what it is

  • Independent, impersonal research on covered public companies.
  • A public experiment with a small real-money account and visible receipts.
  • Tools for watchlists, patience-price alerts, comparison, and process discipline.

what it is not

  • Not personalized investment advice or portfolio management.
  • Not a signal service that must produce trades to justify itself.
  • Not a mature performance claim. The evidence is young and labeled accordingly.

the simplest way to use it

Check the stock. Read the reasons against it. Then watch the receipt.

start with a ticker →open the receipts

Research and education only — not investment advice. Past results do not predict future outcomes.